Tag: VenoValve
Bioprosthetic venous valve imparts sustained clinical improvement at one year regardless...
A new paper that drills into the impact of a novel bioprosthetic venous valve replacement by CEAP (Clinical, Etiological, Anatomical and Pathophysiological) classification shows...
SVS, AVF bring the latest innovations in venous disease treatment to...
During the first day of VAM 2024, the Society for Vascular Surgery (SVS) and American Venous Forum (AVF) have co-sponsored a session on the...
Prosthetic valve implantation shows “vast” improvements in deep chronic venous insufficiency
“The surgical challenges of repairing deep venous reflux have been present for more than a generation. It is worth reflecting on the fact that...
Bioprosthetic venous valve: ‘We want to know that this is really...
A key investigator in efforts to tackle chronic venous insufficiency (CVI) with an bioprosthetic venous valve replacement talks about progress being made with surgical...
AVF 2023: Investigators report update on three-year first-in-human results for bioprosthetic...
Researchers in Colombia behind the first-in-human study of a novel bioprosthetic venous valve designed to treat chronic venous insufficiency (CVI) reported three-year results among...
First-in-human patients continue to benefit from VenoValve at average of three...
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...
The top 10 most popular Vascular Specialist stories in March
Among the posts catching Vascular Specialist readers' eyes last month were the digital flipbook version of our March print edition, a new study looking...
AVF 2022: VenoValve improvement ‘maintained’ for 2.5 years without adverse events
Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum (AVF)...
Envveno Medical reports successful completion of first VenoValve surgery in US...
Envveno Medical—formerly Hancock Jaffe Laboratories—recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has been successfully...
The top 10 most popular Vascular Specialist stories in August
Our recent editorial on the status of the interview, one of the Presidential Addresses from the Vascular Annual Meeting (VAM), a slew of new...
Colombian researchers report positive 24-month results for VenoValve
Promising two-year results for an emerging potential prosthetic venous valve replacement—which is about to commence a U.S. pivotal trial—were announced at the Vascular Annual...
‘The future is very bright for venous valve replacement’
The progress of two “promising” new devices in the venous valve replacement space were outlined during a Vascular Annual Meeting (VAM) special session co-hosted...
VenoValve granted FDA Breakthrough Device designation
Hancock Jaffe Laboratories today (Wednesday, Aug. 4) announced that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the company's...
VenoValve: Chronic venous insufficiency device gains brisk double of first US...
Hancock Jaffe Laboratories recently revealed that the United States Patent and Trademark Office (USPTO) issued the first patent covering the company’s VenoValve. The patent is...
Initial results from first-in-man trial of prosthetic VenoValve demonstrate promise, says...
PALM BEACH, Fla.—The initial results of an ongoing first-in-man study in Colombia that saw the implantation of a prosthetic venous valve in 15 patients...